SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (224)4/26/2002 11:43:07 AM
From: keokalani'nui  Read Replies (1) | Respond to of 508
 
IJ,

I believe you just set the standard for quality in digesting a CC. I didn't think SoftwareS and SnowS (the two double Ss?) could be beat, but there it is. Well, Tuck's up there too. Thanks from everyone. Now make it go up, please.



To: IRWIN JAMES FRANKEL who wrote (224)4/26/2002 12:33:26 PM
From: Elmer  Read Replies (1) | Respond to of 508
 
<Actimmune for IPF>

is the trial double blinded?
Thanks again,
David



To: IRWIN JAMES FRANKEL who wrote (224)4/30/2002 4:55:38 PM
From: rkrw  Read Replies (1) | Respond to of 508
 
Jim,
Many thanks for graciously sharing your cc summary.

One clarification:

<- Announce PEG Infergen partner & start trials w/i 12 months>

This is for the peg supply partner, not a joint venture partner in the classic sense. So enzon, shearwater (inhl) etc. hopefully a supply agreement with very low royalty flow to the supplier.

Come November we're celebrating or crying :-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News